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A B S T R A C T
Despite the lack of evidence of the ability to suppress gastric acid secretion in dogs, ranitidine (RT) is often used
to control clinical signs in dogs with acute vomiting even if the way it happens it is still largely unknown. The
aim of this study was thus to evaluate the therapeutic effect of ranitidine on H2 receptors in dogs with acute
vomiting. To investigate the RT activity a preliminary study was performed in dogs which underwent gastro-
scopy analyses, demonstrating that the level of H2R observed in the serum and gastric wall tissue was the same
[1.473(1.30; 1.79) ng/ml and 1.498 (1.33; 1.85) ng/ml, respectively]. After that H2R levels in the serum of 22
healthy dogs (Group 1) and in a group of 22 dogs with acute vomiting (Group 2) were compared both before
(T0), after 7–10 days (T1) of 2 mg/kg twice a day ranitidine administration and after 11 days since the drug was
discontinued (T2). Significant differences (p<0.001) were detected between the level of circulating H2R among
Group 1: 0.41 ng/ml (0.28;0.54) and Group 2: 2.27 ng/ml (2.11;2.49) at T0. In Group 2, no difference in the
level of H2R was detected in samples collected at T0 compared to those at T1 [T1: 2.32 ng/ml (2.14; 2.49)] and
T2 [T2: 2.30 ng/ml (1.99;2.69)]. In Group 2 all patients but one displayed remission of symptoms attributable to
inflammatory gastropathy at the first withdrawal (T1: 7–10 days), while at the second withdrawal (T2: after 21
days), remission was detected in all dogs. Our preliminary hypothesis is that the clinical efficacy of ranitidine is
related to the greater expression of H2 receptors in patients with acute vomiting. This increased expression may
be due to continuous pathological stimulus at the gastric level. Further studies with a wider population are
needed to better investigate the activity of RT in dogs with acute onset of vomiting.
Introduction
Ranitidine (RT) is one of the antagonists against H2 histamine re-
ceptors (H2R) that clinically decreases gastric acid secretion in human
patients (Panula et al., 2015). H2 histamine receptor antagonists
(H2RA), also called H2 blockers, impede the action of histamine at the
level of H2 histamine receptors (H2R) of parietal cells in the stomach
(Marks et al., 2018). They are competitive antagonists of histamine
which exert their action through complex mechanisms. Histamine re-
leased by Enterochromaffin- like cells (ECL) in the stomach is blocked
from binding on parietal cell H2R (which stimulate acid secretion);
therefore, other substances that promote acid secretion also through the
release of histamine (such as gastrin and acetylcholine) have reduced
effects on parietal cells when the H2R are blocked (Tiligada and
Ennis, 2018). These actions decrease the basal and meal-stimulated
gastric acid secretion (Marks et al., 2018; Panula et al., 2015). In
companion animals, there are few studies concerning the mechanism of
action and efficacy of ranitidine (Marks et al., 2018). In a study RT is
much less effective in increasing gastric pH then famotidine or proton
pomp inhibitors in healthy beagle dogs (Bersenas et al., 2005). More-
over, RT seems not to prevent gastroesophageal reflux in anesthetized
healthy bitches when compared to metoclopramide and placebo
(Favarato et al., 2012). Despite the lack of studies demonstrating its
efficacy, RT is anecdotally used to treat nausea and vomiting in dogs or
to prevent non-steroidal anti-inflammatory drugs side effects in dif-
ferent settings (intravenously in intensive care, subcutaneously in
https://doi.org/10.1016/j.vas.2020.100138
Received 9 October 2019; Received in revised form 20 July 2020; Accepted 20 July 2020
⁎ Corresponding author.
E-mail address: raffaella.barbero@unito.it (R. Barbero).
Veterinary and Animal Science 10 (2020) 100138
Available online 21 July 2020
2451-943X/ © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
T
clinics or prescribed orally for home use) due to its wide maneuver-
ability and safety (Daly and Price, 1983). This preliminary study arises
from the interest in better understanding why ranitidine is perceived as
effective in patients with acute vomiting. Our hypothesis is that in
patients with acute vomiting there could be greater expression and
activation of H2 receptors on the gastric mucosa and, therefore, their
blockage by RT might justify its clinical efficacy.
In order to accomplish this, a preliminary study was performed to
establish the levels of H2 receptors in serum and gastric wall respec-
tively, in a population of dogs that underwent routine gastrointestinal
endoscopy.
Subsequently the variation in serum H2R in the acute vomiting




In a preliminary study, endoscopic examination of the gastro-
intestinal tract was performed in 34 dogs for different clinical reasons:
20 patients with chronic gastro-intestinal symptoms, five dogs with
signs of chronic inflammatory colopathy and nine dogs admitted for
gastric foreign body ingestion.
The endoscopic investigation and biopsies were performed ac-
cording to “Endoscopic, Biopsy, and Histopathologic Guidelines for the
Evaluation of Gastrointestinal Inflammation in Companion Animals”
(Washabau et al., 2010). For each dog, four gastric biopsies were per-
formed (two samples collected from the body and two from inside the
fundus using biopsy forceps with oval and fenestrated 2.4 mm cups)
and 4 ml of whole blood were taken during the usual preoperative
screening. The endoscopic investigation and biopsies were performed
with the owner's permission. All procedures were carried out ex-
clusively after the written consent was signed by the owner. The H2
receptors level measurement was performed (N = 34) using im-
munoenzymatic assay and Western Blot assay techniques for both
serum and tissue samples. Results were then tested to evaluate corre-
lation and are presented in Table 1.
Concentration of H2R in dog sera - animals and experimental design
Due to the correlation between H2R levels in blood and tissue
samples obtained in the preliminary study and to avoid animal suf-
fering, it was decided to evaluate H2R levels in serum samples of the
study populations. In this study, 44 dogs were included. For each dog, a
blood sample was taken to obtain serum to evaluate the dosage of H2R.
All procedures were carried out exclusively after the owner consent
form was signed.
In Group 1 (N = 22) healthy dogs were included. They had no
history of gastrointestinal disease (vomiting, diarrhea, nausea, anor-
exia, weight loss), no drugs were administered in the previous 30 days
and they resulted clinically healthy on physical examination. They went
for the annual check-up screening test (Leishmania or Filaria testing or
generic biochemical control analyses). The serum leftovers were taken
and stored at –80 °C within 24 h until the analysis was performed.
In Group 2 (N = 22) we included dogs showing signs of acute
vomiting (onset within seven days). The following information was
collected from each patient: breed, body weight, age, sex and re-
productive status, clinical and pharmacological anamnesis and clinical
signs. Hematological features were registered when present. As far as
the clinical visit and anamnesis are concerned, patients were assigned
to one of the following groups:
Light vomiting (A): active subject with dehydration below 4%, less
than three episodes of vomiting in 24 h, not anorexic and not in need of
hospitalization.
Heavy vomiting (B): depressed subjects, showing signs of dysorexia
or anorexia or systemic illness and dehydration above 4% and may be
in need of hospitalization (Table 2).
The diagnostic process involved the use of various analyses and
techniques to obtain the diagnosis and to subsequently set up the
therapy. The dogs included in Group 2 were treated with 2 mg/kg of RT
twice a day for 10 days. The treatment was given orally (OS) or in-
travenously (IV), as prescribed by the veterinarian. When necessary,
other drugs were used (Table 2). Before starting the therapy with RT,
2 ml of blood serum were obtained from venipuncture [T0]. Further
sera samples were obtained after 7–10 days [T1] and at 21 days [T2],
eleven days after the therapy was interrupted. All samples were quickly
stored at −80 °C after the collection until the analysis was performed.
The follow-up was performed by medical examination at the same time
of the blood sample collection in group 2. The absence of gastro-
intestinal signs in the further 30 days was checked by phone for group
1. All relevant clinical data are listed in Table 2.
H2 immunoenzymatic assay (serum and tissue)
The analyses were carried out using a commercial detection kit
(Canine HRH2-ELISA Kit- Elabscience Biotechnology Co.,Ltd). The
ELISA test is specific for dog and able of assessing with a satisfactory
degree of sensitivity and specificity the concentration of H2 receptors
both in serum and in tissue homogenates. The test used to detect the
level of Canine Histamine Receptor H2 in serum or tissue, is based on
the principle of biotin double-antibody sandwich technology enzyme-
linked immunosorbent assay. Standard and Samples were added to the
pre-coated wells with objective antibody and streptavidin HRP to form
an immune complex. Then the samples were incubated, washed to re-
move the unbound enzyme and the substrate A and B were added. The
final solution turned blue and then changed into yellow because of the
effect of the acid. The color depth or light was positively correlated
with the concentration of H2R. Intra-assay CV (%) was less than 10%
and Inter-assay CV (%) was less than 15% and the sensitivity by this
assay was 0.1 ng/ml.
Western Blot assay
To confirm obtained results with the immunoenzymatic assay, a
Western Blot procedure was performed for all samples to detect H2R in
accordance to the method described by (Boer et al., 2008) using canine
polyclonal to HRH2 / Histamine H2 Receptor (Life Spain BioSciences
Inc.) (Boer et al., 2008).
Statistical analysis
Data were tested for normality by performing Shapiro-Wilk test.
Wilcoxon test was used to compare the level H2 receptors in the gastric
wall tissue and in the blood at T0, T1 and T2. For the comparison of the
level between sick and healthy dogs the Mann-Whitney U test was
applied. Data were summarized with median and interquartile range
and p value was set at 0.05 (Statistical software package IBM, SPSS
statistic 22).
Table 1.
Biopsy vs Serum H2R concentration (ng/ml). Serum and tissue H2R con-
centration in dogs (N = 34). Wilcoxon Test, P value = 0.005. Interquartile
range H2R serum: (1.30; 0.79). Interquartile range H2R biopsy: (1.33; 1.85).
H2R serum (ng/ml) H2R biopsy (ng/ml)
Dogs N = 34 N = 34
Mean Value 1.473 1.498




In the preliminary study, no difference was detected in the level of
H2 receptors present in serum and in gastric wall tissue [1.473 (1.30;
1.79) ng/ml and 1.498 (1.33; 1.85) ng/ml] respectively by median and
interquartile range (Table 1). These results indicate that concentrations
of H2R are statistically significantly equal both in serum (circulating
receptors) and in gastric tissue.
The subsequent determinations were therefore performed on the
serum. In fact, this result shows that it is possible, in this case, to carry
out tests for diagnosis without additional suffering for the dog.
Concentration of H2R in dog sera
Statistical differences were detected between the level of circulating
H2R among the healthy dogs [Group 1: 0.41 ng/ml (0.28;0.54)] and
sick dogs [Group 2: 2.27 ng/ml(2.11;2.49)] (T0) with p<0.001.
(Graph 1). In group 2, no difference in the level of H2 receptors in the
serum was detected in the samples collected at T0 compared to the
sample collected at T1 [2.32 (2.14; 2.49) ng/ml] and T2 [2.30
(1.99;2.69)] (Table 3). These results indicate that circulating H2R
concentrations are statistically significantly different between healthy
dogs and dogs with gastroenteric pathology. In particular, dogs with
gastroenteric symptoms have a markedly higher concentration of H2
receptors. On the basis of the preliminary study carried out we can also
say that the concentration is higher both at the serum level and at the
level of the stomach wall. Finally, the results show that there are no
significant differences in the concentrations of pathological dog re-
ceptors between T0 T1 and T2. This indicates that the ranitidine ad-
ministration does not change the H2R concentration in this short time.
Table 2.
Clinical data in referred dogs included in the study (N = 22).
ID Breed Age (months) BCS (1–5) Weight (Kg) Sex Vomiting Diagnosis Therapies Resolution of
symptomsA B
1 Bichon-frise 14 3 4,5 SF X Acute aspecific gastritis R Y
2 Mixed breed 96 4 18,4 IF X Chronic hepatitis R + O N
3 Mixed breed 99 5 25,4 NM X Leishmaniasis and acute gastritis R + O Y
4 English setter 94 2 25,2 IM X Gastric foreign body, babesios and
Leishmaniasis
R + O Y
5 Pug 106 3 8 IM X Acute aspecific gastritis R + O Y
6 American Stafforshire
terrier
60 2 24 IF X Idiopathic acute hemorrhagic diarrhea
syndrome
R + O Y
7 Mixed breed 90 3 28 SF X Acute aspecific gastritis R Y
8 Mixed breed 11 2 11 IM X Acute aspecific gastritis R Y
9 Golden retriever 105 4 35,7 IM x Urolithiasis R + O Y
10 Shih-tzu 147 2 6,2 IM X Acute aspecific gastritis R + O Y
11 Labrador retriever 78 4 32 SF X Acute aspecific gastritis R Y
12 Chihuahua 26 4 3,9 NM X Adverse food reaction R Y
13 English bulldog 84 4 24 SF X Acute aspecific gastritis R Y
14 Mixed breed 79 3 7 IM X Acute gastritis due to bone ingestion R Y
15 Mixed breed 42 3 13,2 IM X Adverse food reaction R Y
16 Datchshound 72 4 10,2 IM X Gastric foreing body R + O Y
17 Labrador retriever 108 4 40 SF X Acute aspecific gastritis R Y
18 Jack russel 31 2 4 IF X Acute aspecific gastritis R Y
19 French bulldog 27 3 15 IM X Acute aspecific gastritis R + O Y
20 Staffordshire bull terrier 42 3 17,5 SF X Adverse food reaction R Y
21 Chihuahua 99 3 3,2 SF X Acute gastritis and pyelonefritis R N
22 Labrador retriever 56 3 24,5 SF X Acute aspecific gastritis R Y
Sex: (mc-mi/fi-fs) NM: neutered male; IM: intact male; IF: intact female; SF: spayed female.
Vomiting: A = light-moderate vomiting; B = heavy vomiting.
Resolution of symptoms: Y=Yes; N=no.
Therapy: R = Ranitidine 2 mg/kg OS, EV o SC depending on veterinary surgeon's choice; O]Other drugs depending on dog's pathology (e.g. prednisone, lattulose,
spironolactone, silymarin, ursodeoxycholic acid, allopurinol, imidocarb, ferrous sulfate, maropitant, meloxicam, intravenose fluid therapy, ampicilline, me-
tronidazole).
Graph 1.. Comparison of the average level of H2 receptors found in serum of
Group 1 healthy dogs (N = 22) versus vomiting dogs Group 2 (N = 22) before
starting treatment with ranitidine (T0).
Table 3.
Serum H2 levels in dogs tested at T0, T1 and T2 (N = 22).
T0 T1 T2
Dogs H2R (ng/ml) H2R (ng/ml) H2R (ng/ml)
Total Mean value Mean value Mean value
22 2.27 (ng/ml) 2.32 (ng/ml) 2.30 (ng/ml)
E. Bottero, et al. Veterinary and Animal Science 10 (2020) 100138
3
Clinical data
Group 1 included 22 healthy subjects who went to various
Veterinary Clinics for routine blood tests. None of the dogs developed
vomiting or gastrointestinal disease within 30 days after the collection.
Group 2 included 22 dogs of various breeds and sizes (included six
individuals of mixed breed and four Labrador); sex was equally re-
presented with 11 females (six of which were spayed at the time of the
study) and 11 males; median age was 5.9 (1.2–12.2) years old, mean
weight was 17.3 kg (4.5–40) and BCS (body condition score) clinically
assigned on a 5-point scale at 3.1 (2–5). Fifteen subjects of Group 2
were presented for moderate vomiting (A), while seven patients showed
signs of severe vomiting (B). A GI-tract disease as the primary cause of
vomiting was proven in 17 dogs, (6/17 in group B) while this could not
be affirmed for five of the 22 dogs, which indeed were vomiting for pre-
existent conditions as Leishmaniosis (2 of 5), urethral disease (1 of 5),
pyelonephritis (1 of 5) and hepatic disease (1 of 5). Among the 17 dogs
with proven gastrointestinal conditions, 11 were diagnosed with acute
aspecific gastropathy, four with adverse reaction to food, one dog with
acute hemorrhagic diarrhea syndrome and one with foreign body in-
gestion. Thirteen dogs of Group 2 were treated with ranitidine solely,
while six received an association of RT plus antiemetic, and 3 RT plus
antibiotic (Table 2). In all patients but one (16/17) at the first with-
drawal (7–10 days) remission of symptoms attributable to in-
flammatory gastropathy was noted, while at the second withdrawal
(after 21 days) remission was achieved in all subjects.
Discussion
The H2R belong to a large family of G protein-coupled receptors
(GPCRs) and play important physiological roles in the regulation of
gastric acid secretion, cell differentiation and proliferation, im-
munological response, and central nervous system functions. H2RA has
been widely used to treat acid-related diseases such as peptic ulcer and
reflux oesophagitis in human patients (Monczcor and Fernadez, 2016)(
In the present study, our results reveal a new perspective regarding the
variation in H2R levels in healthy dogs and in those with gastric pa-
thology. The results of the preliminary phase of this study were useful
to be able to consider the receptor concentration H2 superimposable on
the gastric mucosa and in the serum. However, an objective limit of this
evaluation lies in the reduced number of patients and also in the eva-
luation of only sick patients. Performing biopsies in healthy animals
would perhaps be useful, but certainly unethical and therefore it was
chosen not to perform them. A first datum worthy of discussion in the
study regarding dogs with acute vomiting is the statistically significant
difference between H2R levels among healthy dogs and dogs with acute
vomiting. We cannot state that the increase of H2 receptors detectable
in the serum is the expression of a defined gastric pathology; never-
theless the finding of high values in patients with different acute gas-
tropathies and also in the course of pathologies not primarily gastro-
enteric, suggests that histamine can mediate generically gastric re-
activity. It would be interesting to be able to make this comparative
assessment also in patients with chronic inflammatory gastropathy and
in patients with other chronic diseases in which vomiting is a possible
symptom. Moreover comparing the data of our preliminary study per-
formed on chronic patients with gastro-enteric inflammation that un-
derwent endoscopy, a higher median value (1.473 ng / ml) than that of
healthy patients (0.41 ng / ml) was found. In our opinion, these results
are remarkable and should be considered for further studies. The pre-
liminary nature of the data as well as the low number of dogs included
in our study constitutes its main limit; this precluded the investigation
of a relationship between the number of receptors and variables such as
age, breed, sex, or current disease of the animals. Despite these lim-
itations, it would be interesting to evaluate if the value of H2R in the
serum could become a possible biomarker of gastric disease. Further
studies with a wider population are needed to assess this hypothesis and
it might be interesting to evaluate the potential diagnostic role of H2R
in patients with chronic gastrointestinal diseases and with severe vo-
miting of different origin. Obviously in a clinical setting this test could
be unnecessary in self-limiting acute vomiting patients. Following the
results of our study, the authors hypothesize the possible correlation
between the expression of H2R in the stomach during acute pathology
and the efficacy of therapeutic treatment with ranitidine. Indeed, we do
not rule out that greater H2R expression is positively correlated to the
clinical efficacy of RT. This concept deserves further study. In fact we
can also consider that the opposite situation occurs: for example the
down-regulation of H2R or even gene inactivation. This fact could
imply a different expression of the pathology and symptoms and a
different patient response to treatment. At the end of the study all in-
cluded dogs were clinically examined and had a full assessment of their
health status. Following treatment with ranitidine, dogs with acute
gastric disease had either remitted or recovered. Some studies have
shown that dogs do not experience a statistically significant variation of
gastric pH when treated with RT or a placebo (Lidbury et al., 2012;
Bersenas et al., 2005). Similar results have also been reported regarding
the use of ranitidine in cats (Sutalo et al., 2015) and also of famotidine
in dogs (Tolbert et al., 2011). For these reasons, given the widespread
use of RT and its clinical efficacy in treating nausea in dogs, the authors
have attempted to better investigate whether RT interacts with gastric
physiology during acute vomiting of various nature. Histamine re-
ceptors have previously been shown to enhance delayed hypersensi-
tivity and antibody mediated immune responses. This has been ob-
served in many pathological processes regulating several essential
events in experimental animal models, such as allergic conditions and
autoimmune diseases, especially in knock-out mice (either H1- or H2-
deficient)(Rocklin and Beer, 1983; Quintana et al., 2004). Histamine-
mediated signals are largely determined locally by the histamine re-
ceptor expression pattern (Boer et al., 2008). The histaminergic
pathway leading to acid hyper-secretion to counteract a pH increase in
acute vomiting dogs is actively enhanced, but its involvement is only
partially responsible (for about 30%) for the aforesaid acidic release;
indeed a greater expression of H2R in sick patients might explain the
more clinically satisfactory efficacy of ranitidine treatment in this type
of patient (Shahid et al., 2009; Shim and Kim, 2017) The over-
expression of receptors in patients with acute gastritis could allow RT,
which has a higher affinity for H2R only, to have clinical effect without
significantly increasing the pH. Bersenas (Bersenas et al., 2005) has
shown that RT treatment does not increase gastric pH in dogs. However,
the study was performed only on healthy dogs. Although our study is
limited and preliminary, ranitidine showed therapeutic effectiveness in
13 dogs when used as the sole treatment of gastropathies (see Table 2).
In ten of these subjects the vomiting was of light/moderate severity (A),
While in the three animals with severe symptoms (B) and a diagnosis of
adverse food reaction that received ranitidine only, a contextual change
in dietary habits might have had a determinant role in achieving clin-
ical resolution. If we suppose, on the basis of the bibliography
(Bersenas et al., 2005) that in these dogs the RT does not significantly
modify the pH, then its clinical effectiveness could also be due to an-
tagonism towards over-represented receptors. Among the seven dogs
with severe vomiting (B), the employment of RT alone was effective in
three dogs, while in the cases where it was associated with other
treatments, therapeutic synergy with RT (see Table 2) cannot be ex-
cluded.
The obtained results in the last part of our study showed likelihood
to up-regulate the level of H2R in the serum of dogs receiving treat-
ment, although a statistically significant correlation, probably due to
the low number of tested dogs, was not shown. However, the up-reg-
ulation of H2 (as G protein-coupled receptors) in treated dogs proves
the pharmacological efficacy at a molecular level of ranitidine admin-
istration. The level of H2R was still high at the time of the second
sampling (T2) despite the clinical recovery of the dogs’ symptoms.
However, the G proteins coupled receptors showed the tendency to
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modify their concentration more slowly which might justify this result.
It would have been interesting to also evaluate a possible decrease of
H2 receptors in the long-term period, unfortunately we could not
evaluate all 22 dogs a fourth time since the first withdrawal. The design
of this study is subject to some limitations. Unfortunately, the limited
number of cases did not allow to perform further statistical analyses
(such as comparing the results with age, sex, breed and type of diet). No
placebo group was chosen. Moreover, some cases have been treated
with medications other than RT, although no drug with interaction with
H2R other than RT was taken. Another potential limitation is that we
included dogs with multiple diseases. Although it is not proven that the
underlying disorder was the only cause of acute vomiting, we decided
to include such group of patients because they reflect a category in
which RT is commonly used.
Conclusions
In conclusion, the measurement of H2R concentration in the serum
of dogs is reliable as it reflects the level of H2R present in the gastric
wall. Although the number of patients is small, we found a significant
statistic difference between the average level of H2R in healthy dogs
and in dogs with primary or secondary gastropathy. This difference
could be related to the clinical efficacy that ranitidine has shown during
acute vomiting. Therefore we suppose that the clinical effectiveness
could also be due to antagonism towards these overrepresented re-
ceptors. We cannot say that the quantitative evaluation of H2 receptors
has a precise diagnostic and even less therapeutic significance. This
hypothesis will be further investigated by carrying out studies with a
greater number of patients. Moreover it would be necessary to better
define when and if to use receptor research as a non-invasive diagnostic
tool during acute and chronic gastro-enteropathy and consequently
better define the necessity and efficacy of the treatment with ranitidine.
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